Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial

Joris B. W. Elbers, Abrahim Al-Mamgani, Margot E. T. Tesseslaar, Michiel W. M. van den Brekel, Charlotte A. H. Lange, Jacqueline E. van der Wal, Marcel Verheij, Charlotte L. Zuur, Jan Paul de Boer

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background and purpose: Radiotherapy (RT) with cetuximab is an alternative for advanced-stage head and neck squamous cell carcinoma (HNSCC) patients who are unfit for cisplatin treatment. As 5-year overall survival is below 50%, it is of interest to test PD-L1 immune checkpoint blockade (avelumab) with cetuximab-RT in the curative setting. Materials and methods: Phase-I feasibility trial (planned n = 10, NCT02938273) of conventional cetuximab-RT with avelumab (concurrent 10 mg/kg Q2W + 4 months maintenance) for advanced-stage HNSCC patients unfit for cisplatin treatment. Results: One of ten included patients experienced grade 2 cetuximab-related infusion reaction and withdrew from the study before avelumab was administered. One patient discontinued treatment after 2 courses of avelumab and 12×2Gy RT for personal reasons. In 2/8 remaining patients, avelumab was stopped after 4 and 8 courses because of toxicity and tumor progression, respectively. There was no grade 4–5 toxicity. Grade 3 immune-related toxicity was manageable and occurred in 4 patients. One patient was treated with topical steroids for grade 3 maculopapular rash and 3 patients received high-dose prednisone for grade 3 elevated liver enzymes (n = 1) and pneumonitis (n = 2). Seven patients experienced grade 3 RT-related toxicity with no severe specific cetuximab-related toxicity. Tumor recurrence occurred in 4/8 patients (50%) after a median of 12 (8–26) months follow-up. Conclusion: Cetuximab-RT plus avelumab is feasible in patients with advanced-stage HNSCC who are unfit for cisplatin treatment. Immune-related toxicity was transient and manageable and radiotherapy-related toxicity was in accordance with standard of care. This pilot study provides grounds for larger efficacy trials.
Original languageEnglish
JournalRadiotherapy and Oncology
DOIs
Publication statusPublished - 1 Jan 2019
Externally publishedYes

Cite this

Elbers, J. B. W., Al-Mamgani, A., Tesseslaar, M. E. T., van den Brekel, M. W. M., Lange, C. A. H., van der Wal, J. E., ... de Boer, J. P. (2019). Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial. Radiotherapy and Oncology. https://doi.org/10.1016/j.radonc.2019.08.007